PCPeter Socrates Creticos

Peter Socrates Creticos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter Socrates Creticos has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper

    by Oliver Pfaar, Ioana Agache, Karl‐Christian Bergmann, Carsten Bindslev‐Jensen, Jean Bousquet, Peter S. Creticos, Philippe Devillier, Stephen R. Durham, Peter Hellings, Susanne Kaul, et al.

    The placebo (Latin “I will please”) effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients’ expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double‐blind, placebo‐controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials.


  • Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy

    by Désirée E. Larenas-Linnemann, Maria del Carmen Costa-Domínguez, Peter Socrates Creticos


  • Immunotherapy of Allergic Disorders: Traditional and Novel Approaches

    by Jr. Franklin Adkinson, Robert G. Hamilton, Peter S. Creticos, Lawrence M. Lichtenstein, Philip S. Norman

    For approaches to the immunotherapy of allergic respiratory diseases now under study at Johns Hopkins are reviewed. Traditional high dose parenteral immunization with mixtures of allergens corresponding to patients’ allergic sensitivities is being evaluated in the long-term management of allergic asthma in children. Oral desensitization employing doses of short ragweed extract 100 fold higher than for parenteral therapy has been proven safe and efficacious and is now being modified to render it practicable. Intradermal injections of autologous IgG immune complexes with D. pteronyssinus antigens has been reported to improve symptoms and reduce IgE synthesis; a trial to replicate these findings is underway. Immunization with immunodominant peptides from Fel d. I is also under development as a novel immunoregulatory intervention with potential clinical application.